TY - JOUR
T1 - Clinical implications of microsomal prostaglandin E synthase-1 overexpression in human non-small-cell lung cancer
AU - Wang, Hao Wei
AU - Hsueh, Chung Tsen
AU - Lin, Chien Fu Jeff
AU - Chou, Teh-Ying
AU - Hsu, Wen Hu
AU - Wang, Liang Shun
AU - Wu, Yu Chung
N1 - Funding Information:
The authors thank Kuan-Hua Chen, Chia-Li Lu and Li-Ling Yang for their excellent technical assistance. This work was supported by grants from the Taipei Veterans General Hospital (VGH93-64; Y-CW) and the Taiwan National Science Council (92-2314-B-039-009; C-TH).
PY - 2006/9
Y1 - 2006/9
N2 - Background: Microsomal prostaglandin E synthase-1 (mPGES-1) has recently been found to overexpress in human cancers, including non-small-cell lung cancer (NSCLC). However, the clinical value is largely unknown. The aim of this study was to investigate the associations between mPGES-1 expression in NSCLC and the clinical characteristics and survival outcome. Methods: Between 2001 and 2003, paired fresh tumorous and nontumorous samples were prospectively procured from patients undergoing surgery for NSCLC. The expression of mPGES-1 was assessed by using Western blot in 93 subjects and reverse transcriptase-polymerase chain reaction in 35. Overexpression of mPGES-1 was defined as a more than 2-fold expression in the tumorous sample compared with the corresponding nontumorous one. Immunohistochemistry was used to confirm its localization to the tumor cells. In a subset of 30 cases, cyclooxygenase-2 (COX-2) was also analyzed to assess its association with mPGES-1. Results: The protein and messenger RNA of mPGES-1 were both expressed at higher levels in the tumor samples (P < .001 and P = .006, respectively). The expressions of mPGES-1 and COX-2 were unrelated (P = .715). Overexpression of mPGES-1 protein was observed in 61 (65.6%) of 93 patients, but it was not significantly associated with the clinicopathologic characteristics or overall and disease-free survivals. However, mPGES-1 overexpression seemed to be associated with the likelihood of subsequent pulmonary metastases and a lower tendency for developing bony metastases (P = .001 and P = .006, respectively). Conclusions: Our results demonstrated that mPGES-1 was overexpressed in NSCLC, unassociated with COX-2. Overexpression of mPGES-1 per se was not a prognostic indicator, but it might be implicated in the organ preference of metastasis. Published by Springer Science+Business Media, Inc.
AB - Background: Microsomal prostaglandin E synthase-1 (mPGES-1) has recently been found to overexpress in human cancers, including non-small-cell lung cancer (NSCLC). However, the clinical value is largely unknown. The aim of this study was to investigate the associations between mPGES-1 expression in NSCLC and the clinical characteristics and survival outcome. Methods: Between 2001 and 2003, paired fresh tumorous and nontumorous samples were prospectively procured from patients undergoing surgery for NSCLC. The expression of mPGES-1 was assessed by using Western blot in 93 subjects and reverse transcriptase-polymerase chain reaction in 35. Overexpression of mPGES-1 was defined as a more than 2-fold expression in the tumorous sample compared with the corresponding nontumorous one. Immunohistochemistry was used to confirm its localization to the tumor cells. In a subset of 30 cases, cyclooxygenase-2 (COX-2) was also analyzed to assess its association with mPGES-1. Results: The protein and messenger RNA of mPGES-1 were both expressed at higher levels in the tumor samples (P < .001 and P = .006, respectively). The expressions of mPGES-1 and COX-2 were unrelated (P = .715). Overexpression of mPGES-1 protein was observed in 61 (65.6%) of 93 patients, but it was not significantly associated with the clinicopathologic characteristics or overall and disease-free survivals. However, mPGES-1 overexpression seemed to be associated with the likelihood of subsequent pulmonary metastases and a lower tendency for developing bony metastases (P = .001 and P = .006, respectively). Conclusions: Our results demonstrated that mPGES-1 was overexpressed in NSCLC, unassociated with COX-2. Overexpression of mPGES-1 per se was not a prognostic indicator, but it might be implicated in the organ preference of metastasis. Published by Springer Science+Business Media, Inc.
KW - Cyclooxygenase inhibitors
KW - Non-small-cell lung cancer
KW - Prostaglandin-endoperoxide synthase
KW - Prostaglandins
UR - http://www.scopus.com/inward/record.url?scp=33748978607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748978607&partnerID=8YFLogxK
U2 - 10.1245/s10434-006-9001-4
DO - 10.1245/s10434-006-9001-4
M3 - Article
C2 - 16952028
AN - SCOPUS:33748978607
SN - 1068-9265
VL - 13
SP - 1224
EP - 1234
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 9
ER -